Latest news with #BNT113
Scottish Sun
5 days ago
- Health
- Scottish Sun
Brits fast-tracked onto NHS trial of ‘game-changing' cancer vaccine to combat sex-related cases
'These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses,' one expert says PEOPLE with head and neck cancer will be given fast-track access to a new "transformative" cancer jab. The injection targets advanced forms of the devastating disease, giving patients "renewed hope of holding it at bay". Advertisement 2 More than 100 patients are expected to be recruited onto the trial Credit: PA It works by boosting the immune system's response by using Covid jab-style mRNA technology helping it 'attack' cancer cells containing human papillomavirus (HPV) proteins. Up to 70 per cent of all head and neck cancers are linked to HPV, a virus often spread via sex. This move adds to the NHS England's Cancer Vaccines Launch Pad programme, which has already helped 550 bowel and skin cancer patients. More than 100 patients with advanced head and neck cancer are expected to benefit from the jab through the AHEAD-MERIT (BNT113) trial, running at 15 hospitals over the next year. Advertisement Head and neck cancer is a general term to describe forms of the disease in those regions of the body, and can include cancer of the mouth, throat or voice box. Around 11,000 new cases are diagnosed in England every year. HPV is a common virus spread through close contact, including sex and childbirth. Advertisement Most HPV infections clear naturally without causing symptoms. 'Low-risk' types may cause warts, like genital warts or verrucas on hands and feet. But at least 14 'high-risk' types can sometimes trigger cancer. Rock star devastated as he's diagnosed with 'very aggressive' cancer and shares snap from hospital bed Despite treatment advances, aggressive head and neck cancers remain tough to beat, with high recurrence rates and less than 50 per cent surviving beyond two years. Advertisement The vaccine used in the study has been designed to create two proteins that are commonly found in head and neck cancers associated with high-risk types of HPV. These types of cancer, known as squamous cell cancers, develop from flat, scale-like cells in the outer layer of the skin and other areas of the body. Health minister Karin Smyth described the plan as a "massive win for cancer patients". She added: "These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses. Advertisement "By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation, improving outcomes for people living with cancer." NHS England has joined forces with life sciences company BioNTech to help identify potentially eligible patients to refer to NHS hospitals running the trial. 2 The trial is the third to be run through the NHS Cancer Vaccine Launch Pad, which is supported by the Cancer Research UK-funded Southampton Clinical Trials Unit. Advertisement Professor Peter Johnson, national clinical director for cancer at NHS England, said: "It's fantastic that more patients with advanced head and neck cancers will now be able to access this potentially transformative vaccine, offering renewed hope of holding the disease at bay." Tamara Kahn, chief executive at Oracle Head & Neck Cancer UK, said the trial "offers crucial hope to those living with advanced stages of cancer". "While we advocate for HPV vaccination to prevent these cancers, those already fighting this devastating disease urgently need new treatments that could mean more time with loved ones," she added. 'It'll allow people to get on with their lives' Chris Curtis was diagnosed with HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. Advertisement The 67-year-old, from Blackpool, said: "As a survivor of HPV-related head and neck cancer, I know first-hand the physical, emotional, and psychological toll this disease takes not just on the patient, but on the entire support system around them. "With this aggressive cancer you live in the fear of reoccurrence every day - so anything that could help control the disease or give people peace of mind is groundbreaking - it'll allow people to get on with their lives and move forward." The Cancer Vaccine Launch Pad - a partnership between NHS England, the Government and BioNTech - has already helped refer about 550 patients to trials for vaccines for bowel and skin cancers. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: "The Cancer Vaccines Launch Pad is an important route to fast-track promising mRNA vaccine technology into clinical trials. Advertisement "Research into personalised cancer treatments is vital. "There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone. "That's why it's vital that we support a wide range of research, so that more people can live longer, better lives, free from the fear of cancer."
Medscape
5 days ago
- Health
- Medscape
NHS to Fast-Track Patients into mRNA Cancer Vaccine Trial
Patients in England with advanced head and neck cancers will be fast-tracked into a trial of a new cancer vaccine using mRNA technology. The investigational vaccine is designed to help the immune system recognise and destroy cancer cells containing human papillomavirus (HPV) proteins. NHS England said more than 100 patients will be matched to the trial over the next year at 15 NHS hospitals. Third Trial via Cancer Vaccine Launch Pad This is the third cancer vaccine study run through NHS England's Cancer Vaccine Launch Pad (CVLP), a national programme that matches eligible patients with nearby trials. Other CVLP trials are investigating vaccines for patients with colorectal carcinoma and with melanoma. The initiative is coordinated by the University of Southampton's Clinical Trials Unit. Difficult to Treat, High Recurrence More than 11,000 new head and neck cancer cases are diagnosed each year in England. Despite improvements in care, the advanced form of the disease is difficult to treat and has high rates of recurrence, with 2-year survival rates below 50%. The investigational vaccine, known as BNT113, encodes two oncoproteins commonly found in HPV16-positive head and neck squamous cell carcinoma – the most common type, accounting for 95% of these types of cancers. The AHEAD-MERIT trial is an open-label phase II/III randomised study. It will assess BNT113 in combination with pembrolizumab, a PD-1 inhibitor, versus pembrolizumab alone as a first-line treatment for patients with unresectable, recurrent, or metastatic HPV16-positive head and neck cancers expressing PD-L1. 'Potentially Transformative' Approach Professor Peter Johnson, NHS England's national clinical director for cancer, called the vaccine 'potentially transformative' and said it offered 'renewed hope of holding the disease at bay'. Chris Curtis, who was diagnosed with HPV-related head and neck cancer in 2011 and founded the support charity The Swallows, said the vaccine could help people 'get on with their lives and move forward'. Expanding Access to Personalised Treatment The CVLP is part of a strategic partnership between NHS England, the government, and BioNTech. NHS England said it has accelerated cancer trial activity, with faster site activation and enrolment compared with standard processes. The programme aims to match thousands more cancer patients to vaccine and immunotherapy trials in the future. In April, NHS England announced that patients with advanced melanoma would be fast-tracked into the SCOPE study, a clinical trial for a new cancer vaccine. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said the CVLP was 'an important route to fast-track promising mRNA vaccine technology into clinical trials.' He added, 'Research into personalised cancer treatments is vital.'
The Sun
5 days ago
- Health
- The Sun
Brits fast-tracked onto NHS trial of ‘game-changing' cancer vaccine to combat sex-related cases
PEOPLE with head and neck cancer will be given fast-track access to a new "transformative" cancer jab. The injection targets advanced forms of the devastating disease, giving patients "renewed hope of holding it at bay". 2 It works by boosting the immune system's response by using Covid jab-style mRNA technology helping it 'attack' cancer cells containing human papillomavirus (HPV) proteins. Up to 70 per cent of all head and neck cancers are linked to HPV, a virus often spread via sex. This move adds to the NHS England's Cancer Vaccines Launch Pad programme, which has already helped 550 bowel and skin cancer patients. More than 100 patients with advanced head and neck cancer are expected to benefit from the jab through the AHEAD-MERIT (BNT113) trial, running at 15 hospitals over the next year. Head and neck cancer is a general term to describe forms of the disease in those regions of the body, and can include cancer of the mouth, throat or voice box. Around 11,000 new cases are diagnosed in England every year. HPV is a common virus spread through close contact, including sex and childbirth. Most HPV infections clear naturally without causing symptoms. 'Low-risk' types may cause warts, like genital warts or verrucas on hands and feet. But at least 14 'high-risk' types can sometimes trigger cancer. Rock star devastated as he's diagnosed with 'very aggressive' cancer and shares snap from hospital bed Despite treatment advances, aggressive head and neck cancers remain tough to beat, with high recurrence rates and less than 50 per cent surviving beyond two years. The vaccine used in the study has been designed to create two proteins that are commonly found in head and neck cancers associated with high-risk types of HPV. These types of cancer, known as squamous cell cancers, develop from flat, scale-like cells in the outer layer of the skin and other areas of the body. Health minister Karin Smyth described the plan as a "massive win for cancer patients". She added: "These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses. "By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation, improving outcomes for people living with cancer." NHS England has joined forces with life sciences company BioNTech to help identify potentially eligible patients to refer to NHS hospitals running the trial. 2 The trial is the third to be run through the NHS Cancer Vaccine Launch Pad, which is supported by the Cancer Research UK-funded Southampton Clinical Trials Unit. Professor Peter Johnson, national clinical director for cancer at NHS England, said: "It's fantastic that more patients with advanced head and neck cancers will now be able to access this potentially transformative vaccine, offering renewed hope of holding the disease at bay." Tamara Kahn, chief executive at Oracle Head & Neck Cancer UK, said the trial "offers crucial hope to those living with advanced stages of cancer". "While we advocate for HPV vaccination to prevent these cancers, those already fighting this devastating disease urgently need new treatments that could mean more time with loved ones," she added. 'It'll allow people to get on with their lives' Chris Curtis was diagnosed with HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. The 67-year-old, from Blackpool, said: "As a survivor of HPV-related head and neck cancer, I know first-hand the physical, emotional, and psychological toll this disease takes not just on the patient, but on the entire support system around them. "With this aggressive cancer you live in the fear of reoccurrence every day - so anything that could help control the disease or give people peace of mind is groundbreaking - it'll allow people to get on with their lives and move forward." The Cancer Vaccine Launch Pad - a partnership between NHS England, the Government and BioNTech - has already helped refer about 550 patients to trials for vaccines for bowel and skin cancers. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: "The Cancer Vaccines Launch Pad is an important route to fast-track promising mRNA vaccine technology into clinical trials. "Research into personalised cancer treatments is vital. "There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone. "That's why it's vital that we support a wide range of research, so that more people can live longer, better lives, free from the fear of cancer."
ITV News
5 days ago
- Health
- ITV News
Patients to be fast-tracked on to new head and neck cancer vaccine trial
People with head and neck cancer in England will be fast-tracked on to a clinical trial for a 'potentially transformative' vaccine under new NHS plans. The first patients have received the jab, which uses mRNA technology to train the immune system to fight cancer, with more set to be enrolled at their nearest NHS hospital. Head and neck cancer is a general term to describe forms of the disease in those regions of the body, and can include cancer of the mouth, throat or voice box. Around 11,000 new cases are diagnosed in England every year. Aggressive forms are difficult to treat, with high rates of recurrence and two-year survival rates under 50%. The vaccine used in the study has been designed to create two proteins that are commonly found in head and neck cancers associated with high-risk types of human papillomavirus (HPV). These types of cancer, known as squamous cell cancers, develop from flat, scale-like cells in the outer layer of the skin and other areas of the body. More than 100 patients with advanced forms of the disease will be matched to the trial, known as AHEAD-MERIT (BNT113), which will run at 15 hospitals over the next year. Health minister Karin Smyth described the plan as a 'massive win for cancer patients'. She added: 'These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses. 'By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation, improving outcomes for people living with cancer.' NHS England has joined forces with life sciences company BioNTech to help identify potentially eligible patients to refer to NHS hospitals running the trial. The trial is the third to be run through the NHS Cancer Vaccine Launch Pad, which is supported by the Cancer Research UK-funded Southampton Clinical Trials Unit. Professor Peter Johnson, national clinical director for cancer at NHS England, said: 'It's fantastic that more patients with advanced head and neck cancers will now be able to access this potentially transformative vaccine, offering renewed hope of holding the disease at bay.' Tamara Kahn, chief executive at Oracle Head & Neck Cancer UK, said the trial 'offers crucial hope to those living with advanced stages of cancer'. 'While we advocate for HPV vaccination to prevent these cancers, those already fighting this devastating disease urgently need new treatments that could mean more time with loved ones,' she added. Chris Curtis was diagnosed with HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. The 67-year-old, from Blackpool, said: 'As a survivor of HPV-related head and neck cancer, I know first-hand the physical, emotional, and psychological toll this disease takes not just on the patient, but on the entire support system around them. 'With this aggressive cancer you live in the fear of reoccurrence every day – so anything that could help control the disease or give people peace of mind is groundbreaking – it'll allow people to get on with their lives and move forward.' The Cancer Vaccine Launch Pad – a partnership between NHS England, the Government and BioNTech – has already helped refer about 550 patients to trials for vaccines for bowel and skin cancers. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: 'The Cancer Vaccines Launch Pad is an important route to fast-track promising mRNA vaccine technology into clinical trials. 'Research into personalised cancer treatments is vital. 'There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone. 'That's why it's vital that we support a wide range of research, so that more people can live longer, better lives, free from the fear of cancer.'
South Wales Argus
5 days ago
- Health
- South Wales Argus
Patients to be fast-tracked on to new head and neck cancer vaccine trial
The first patients have received the jab, which uses mRNA technology to train the immune system to fight cancer, with more set to be enrolled at their nearest NHS hospital. Head and neck cancer is a general term to describe forms of the disease in those regions of the body, and can include cancer of the mouth, throat or voice box. Around 11,000 new cases are diagnosed in England every year. Aggressive forms are difficult to treat, with high rates of recurrence and two-year survival rates under 50%. The vaccine used in the study has been designed to create two proteins that are commonly found in head and neck cancers associated with high-risk types of human papillomavirus (HPV). These types of cancer, known as squamous cell cancers, develop from flat, scale-like cells in the outer layer of the skin and other areas of the body. More than 100 patients with advanced forms of the disease will be matched to the trial, known as AHEAD-MERIT (BNT113), which will run at 15 hospitals over the next year. Health minister Karin Smyth described the plan as a 'massive win for cancer patients'. She added: 'These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses. 'By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation, improving outcomes for people living with cancer.' NHS England has joined forces with life sciences company BioNTech to help identify potentially eligible patients to refer to NHS hospitals running the trial. The trial is the third to be run through the NHS Cancer Vaccine Launch Pad, which is supported by the Cancer Research UK-funded Southampton Clinical Trials Unit. Professor Peter Johnson, national clinical director for cancer at NHS England, said: 'It's fantastic that more patients with advanced head and neck cancers will now be able to access this potentially transformative vaccine, offering renewed hope of holding the disease at bay.' Tamara Kahn, chief executive at Oracle Head & Neck Cancer UK, said the trial 'offers crucial hope to those living with advanced stages of cancer'. 'While we advocate for HPV vaccination to prevent these cancers, those already fighting this devastating disease urgently need new treatments that could mean more time with loved ones,' she added. Chris Curtis was diagnosed with HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. The 67-year-old, from Blackpool, said: 'As a survivor of HPV-related head and neck cancer, I know first-hand the physical, emotional, and psychological toll this disease takes not just on the patient, but on the entire support system around them. 'With this aggressive cancer you live in the fear of reoccurrence every day – so anything that could help control the disease or give people peace of mind is groundbreaking – it'll allow people to get on with their lives and move forward.' The Cancer Vaccine Launch Pad – a partnership between NHS England, the Government and BioNTech – has already helped refer about 550 patients to trials for vaccines for bowel and skin cancers. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: 'The Cancer Vaccines Launch Pad is an important route to fast-track promising mRNA vaccine technology into clinical trials. 'Research into personalised cancer treatments is vital. 'There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone. 'That's why it's vital that we support a wide range of research, so that more people can live longer, better lives, free from the fear of cancer.'
